Interim Report third quarter 2026

NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Interim report for the third quarter 2026. The report is available on the company´s website: www.nextcellpharma.com. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period last year. Please note that, as of 2025, the Company's financial year corresponds to the calendar year.

Third quarter (July 1, 2026-September 30, 2026)

- Operating income SEK 2.8 million (3.5)
- Net sales SEK 2.7 million (3.4), of which Cellaviva contributed SEK 2.6 million (3.4)
- Profit/loss after financial items SEK –7.5 million (-6.8)
- Cash and cash equivalents SEK 13.9 million (36.1)
- Cashflow from operating activities SEK-7.4 million (-10.5)
- Total cashflow SEK -7.1 million (-10.8)
- Earnings per share* SEK -0.06 (-0.06)
- Equity ratio** 73 (87) percent

First nine months (January 1, 2026-September 30, 2026)

- Operating income SEK 8.6 million (8.4)
- Net sales SEK 8.4 million (8.2), of which Cellaviva contributed SEK 8.1 million (7.5)
- Profit/loss after financial items SEK –29.6 million (-25.6)
- Cash and cash equivalents SEK 13.9 million (36.1)
- Cashflow from operating activities SEK-26.8 million (-27.0)
- Total cashflow SEK -12.1 million (3.4)
- Earnings per share* SEK -0.24 (-0.26)
- Equity ratio** 73 (87) percent

**Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the third quarter: 126,392,959 (111,392,959) shares. The average number of shares for the first nine months: 121,887,464 (97,277,665) shares. The number of shares in NextCell as of 30 September 2026: 126,392,959 (111,392,959) shares.*
***Equity ratio: Shareholders' equity as a percentage of total assets.*

Significant events and news during the third quarter

- NextCell has been selected as the only Swedish company to participate in the EU-Japan Biotech Business Mission 2026. At the same time, the Company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and

Technology Park (HSITP). NextCell will also participate as a Founding Partner in the Nordic Future Health Pavilion at BIOHK 2026.

- NextCell presented its clinical development programme in type 1 diabetes at the INNODIA Symposium on T1D Therapies, held in connection with the European Association for the Study of Diabetes (EASD) 2026 meeting in Milan on 28 September. The presentation will focus on NextCell's clinical programme for NXTCL-T1D, including long-term data from adult patients showing preservation of endogenous insulin production for more than six years following a single infusion.

Significant events after the reporting period

- On 26th of October the 12-month result from ProTrans-Young was announced. In the predefined age group of 7–11 years, children treated with NXTCL-T1D had, on average, preserved a greater proportion of their endogenous insulin production after 12 months and experienced a smaller increase in insulin requirements compared with those receiving placebo. The study did not meet its primary efficacy endpoint in the overall study population. A preliminary analysis of 24-month data from the older age group shows no clear treatment effect, although the data have not yet been fully analysed or validated. NextCell's commercialisation strategy for adults remains unchanged, while the Company intends to refine its treatment strategy for children and adolescents, focusing on treatment timing and the number of administrations. Further analyses are also planned to investigate how age and individual disease progression may influence treatment response.
- The Company's Chief Scientific Officer, Dr Lindsay Davies, presented at BIO-Europe 2026 in Cologne, Germany. Her presentation addressed the challenges of taking allogeneic cell therapies from clinical development to commercial production.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication, on November 26, 2026, about 07:30 AM CET.

For more information, please contact:

Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: +46 (0)8-735 55 95
E-mail: info@nextcellpharma.com
Website: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser

The company's shares are listed on the Nasdaq First North Growth Market.
RedEye Noridc Growth AB is the company´s Certified Adviser.

About NextCell Pharma AB

NextCell is a clinical-stage cell therapy company developing the proprietary NXTCL™ platform for the treatment of immune-mediated diseases, with a primary candidate in type 1 diabetes. NXTCL is designed to enable allogeneic cell therapies with controlled immunomodulation, consistent potency and scalable manufacturing. The company's lead program in type 1 diabetes has shown potential to preserve insulin production and slow disease progression for several years after a single treatment. The group also includes the wholly owned subsidiaries NextCell Sverige, NextCell Hong Kong, Cellaviva and QVance. The company was founded in 2014 and is headquartered in Huddinge next to the Karolinska University Hospital.